直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Prosecution First Blog

No Cause of Action for New Party to Reexamination

February 12, 2016

Authored and Edited by Shawn S. Chang; Amanda K. Murphy, Ph.D.

CAFC Decision: Agilent Technologies, Inc. v. Waters Technologies Corp., No. 15-1280 (Fed. Cir. January 29, 2016)

Background: During an inter partes reexamination requested by Aurora, Agilent acquired “substantially all” of Aurora’s assets and agreed to be bound by the outcome of the reexamination and the underlying patent infringement litigation.

Issue: Under 35 U.S.C. § 141, should Agilent be considered a third-party requester for purposes of appealing the final decision issued by the Patent Trial and Appeal Board in the inter partes reexamination?

Outcome: The Federal Circuit held that Agilent lacked a cause of action to appeal because it is not an appropriate party under 35 U.S.C. § 141.  Reviewing the relevant statutes (35 U.S.C. § 141 and 35 U.S.C. § 315(b)), the Court noted that “these two provisions thus appear, on their face, to confer the right to appeal an adverse reexamination decision only on patent owners and third-party requesters.”  Slip op. at 7.  In addressing the question of whether privies have a cause of action to appeal, the Court noted that 35 U.S.C. § 317 explicitly stops privies from requesting or maintaining certain inter partes reexaminations against the same patent.  According to the Court, the fact that § 141 does not contain similar language indicates that Congress recognized the difference between the third-party requester and its privies. “Because Congress explicitly provided for appeals of reexaminations by third-party requesters but not privies,” the Court concluded that “mere privies lack a cause of action to appeal.” Slip op. at 9.  The Court declined to decide whether a successor-in-interest becomes a third-party requester for purposes of appeal because Agilent failed to establish itself as Aurora’s successor-in-interest.  The Court found that Agilent’s acquisition of “substantially all” of Aurora’s assets does not mean “all.”  Slip op. at 11.  Further, the Court found that even after the transaction, Aurora remained “a distinct, ongoing entity” during the reexamination and “a party to the underlying district court litigation.” Id. Accordingly, the Federal Circuit found that because Agilent did not request the reexamination and failed to establish itself as Aurora’s successor-in-interest, Agilent lacked a statutory cause of action to appeal the reexamination decision.

Prosecution Takeaway:  New parties to reexamination proceedings should be joined by the third-party requesters to have a cause of action for appeal.

Tags

United States Court of Appeals for the Federal Circuit (CAFC)

Contacts

Shawn S. Chang
Of Counsel
Atlanta, GA
+1 404 653 6455
Email
Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP